CA
NZ
UK
AU
IND
US
Research and development expense was US$5,542,281, versus US$4,584,131, which the company tied to its NEXICART-2 clinical trial and other CAR-T clinical andManufacturingactivities. It noted that no CIRM grant reimbursements were received in the quarter, compared with approximately US$1.1 million a year earlier, which had …
General and administrative expenses were US$5,859 thousand, versus US$6,433 thousand. The company tied the decrease primarily to a US$0.7 million decrease in stock-based compensation. Total operating expenses were US$14,477 thousand versus US$9,803 thousand, and the loss from operations equaled those amounts.
The company tied the HCC trial increase to changes in total trial costs from trial scope changes, and the TTI-109 decrease to higher costs in the third quarter of 2025 when its healthy volunteer study began. General and administrative expenses were US$1,854 thousand, versus …
Subscription revenue was US$3.6 million, versus US$1.5 million. The company said it ended the quarter with more than 142,000 paying Owlet360 subscribers. Revenue for the nine months was US$86.7 million, versus US$79.6 million.
The net loss before noncontrolling interest and preferred dividends was approximately US$13 million, versus US$6 million a year earlier. Net loss attributable to PAVM common stockholders was US$11.8 million, which management said remains subject to the finalDebtvaluation analysis. The non-GAAP adjusted loss was US$1.2 …
Net loss was US$6.4 million, or US$(0.42) per share, versus US$6.6 million, or US$(0.62) per share, a year earlier. Adjusted EBITDA, a non-GAAP measure, was US$(5.5) million, versus US$(6.0) million. For the nine months ended September 30, net product revenue was US$31.2 million, up …
Research and development expenses were US$4,219 thousand versus US$1,203 thousand, an increase of US$3.0 million that the company attributed to Phase 3 drug manufacturing costs and continuation of the Phase 2 clinical trial of stenoparib. A one-time expense of US$3.2 million for manufacturing of …
The company's common stock is listed on the New York Stock Exchange. The report was signed by Chief Executive Officer Maria Maccecchini.
Dana Incorporated announced on November 13, 2026 the pricing, expiration, and results of its tender offers to purchase for cash its outstanding 4.250% Senior Notes due 2030 and 4.500% Senior Notes due 2032, with $357,873,000 aggregate principal amount validly tendered by the expiration date.
First Horizon Bank (NYSE:FHN) issued an 8-K press release on November 13, 2026, announcing its participation in New Markets Tax Credit financing for a $25 million Family Opportunity Center in north Houston, alongside Catholic Charities of the Archdiocese of Galveston-Houston and CDFI AltCap.
Please wait processing your request...